NLRP3 inhibition attenuates the allergic rhinitis symptoms in a mouse model
Asian Pacific Journal of Allergy and Immunology · 2024
DOI: 10.12932/ap-301223-1756 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2024. Verfasst von Minhyung Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine and Research Institute for Convergence of Biomedical Science and Technol…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Rhinitis, Allergic.
Abstract (Originalsprache)
BACKGROUND: Recent human and animal studies have demonstrated that Nod-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is closely involved in the development of allergic diseases. OBJECTIVE: To identify the mechanism underlying the activation of NLRP3 inflammasome signaling pathway in an ovalbumin (OVA)-induced allergic rhinitis (AR) mice model and to validate the effect of a specific inhibitor of the NLRP3, MCC950. METHODS: Mice were divided into three groups and each group consisted of ten mice (saline group, the negative control group; OVA group, the OVA-induced AR model group; and OVA+MCC group, treated with 10 mg/kg MCC950). MCC950 was administered intraperitoneally every second day. Multiple parameters of AR, including NLRP3, caspase-1, interleukin (IL)-1β, and IL-18 were evaluated by using ELISA, RT-qPCR, histopathology, and immunohistochemistry. RESULTS: The mRNA and protein levels of NLRP3, caspase-1, IL-1β and IL-18 were upregulated in the OVA group compared with those of the saline group. MCC950 significantly inhibited the mRNA and protein levels of NLRP3, caspase-1, IL-1β and IL-18 in nasal tissue. Further, AR symptoms and eosinophil count were normalized after MCC950 treatment. However, OVA-specific IgE was not restored in the OVA+MCC group. CONCLUSION: NLRP3 inflammasome signaling pathway may be an alternative pathway to induce AR symptoms in OVA-induced AR model. MCC950 is a specific inhibitor of NLRP3 cascade, which attenuates AR symptoms regardless of IgE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of…
- Graduate School of Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Allergy Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Center of Morphological Experiment, Medical College of Yanbian University, Yanji, China.
- Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Zitieren
APA
Lee, M., Ko, Y. K., Jang, S., Gil, C. H., Eun, K. M., Zhang, Y. L., Cho, S. W., Kim, D. W., Kim, H. J., & Rhee, C. S. (2024). NLRP3 inhibition attenuates the allergic rhinitis symptoms in a mouse model. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-301223-1756
Vancouver
Lee M, Ko YK, Jang S, Gil CH, Eun KM, Zhang YL, et al. NLRP3 inhibition attenuates the allergic rhinitis symptoms in a mouse model. Asian Pacific Journal of Allergy and Immunology. 2024. doi:10.12932/ap-301223-1756
BibTeX
@article{Lee2024,
author = {Lee, Minhyung and Ko, Young-Kyung and Jang, Sehun and Gil, Chan Hee and Eun, Kyoung Mi and Zhang, Yu-Lian and Cho, Sung-Woo and Kim, Dae Woo and Kim, Hyun Jik and Rhee, Chae-Seo},
title = {NLRP3 inhibition attenuates the allergic rhinitis symptoms in a mouse model},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2024},
doi = {10.12932/ap-301223-1756}
}
EUVIMED